SCHEMBL13628101

SCHEMBL13628101

COc1cccc(-c2ccc3c(c2)N(Cc2cc(=O)oc4cc(OC)ccc24)C(=O)/C3=N\O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 5/20 0.48
KDM4E B2RXH2 6/20 0.47
ALDH1A1 P00352 5/20 0.47
POLB P06746 1/20 0.47
LCK P06239 1/20 0.45
CA12 O43570 2/20 0.45
CA9 Q16790 2/20 0.45
HPGD P15428 3/20 0.45
CYP2D6 P10635 2/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
MAPT P10636 1/20 0.43
NPC1 O15118 1/20 0.43
HSD17B10 Q99714 2/20 0.43
LMNA P02545 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
USP2 O75604 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPK1 P28482 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628106 0.91 CYP19A1 (0.47) CYP19A1KDM4EALDH1A1POLBLCK
SCHEMBL13628114 0.89 CYP19A1 (0.46) CYP19A1KDM4EALDH1A1POLBLCK
SCHEMBL13628095 0.89 CYP19A1 (0.46) CYP19A1KDM4EALDH1A1POLBLCK
SCHEMBL13910880 0.86 CYP19A1 (0.46) CYP19A1KDM4EALDH1A1POLBLCK
SCHEMBL13628130 0.86 CYP19A1 (0.46) CYP19A1KDM4EALDH1A1POLBLCK
SCHEMBL13910973 0.85 CYP19A1 (0.44) CYP19A1KDM4EALDH1A1POLBLCK
SCHEMBL13628121 0.85 CYP19A1 (0.49) CYP19A1KDM4EALDH1A1POLBLCK
SCHEMBL13628102 0.74 TRPA1 (0.48) KDM4EALDH1A1POLBHPGDMAPT
SCHEMBL13628099 0.74 RAB9A (0.46) ALDH1A1POLBHPGDMAPTNPC1
SCHEMBL13628098 0.74 HTR1A (0.49) KDM4EALDH1A1HPGDMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 CYP19A1 4684/4885KDM4E 2171/4885ALDH1A1 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.